$R^{5'}$ is hydrogen, or R^5 and $R^{5'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^6 and R^7 are independently hydrogen or C_1-C_4 alkyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^9 is C_1-C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^{10} is hydrogen or C_1-C_4 alkyl;

R^{11} is C_1-C_4 alkyl or C_1-C_4 acyl;

R^{12} is hydrogen, halo, or C_1-C_4 alkyl;

R^{13} is hydrogen, C_1-C_4 alkyl, or benzyl;

R^{14} is hydrogen, C_1-C_4 alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

or pharmaceutically acceptable acid addition salts thereof.

2. A pharmaceutical formulation which comprises, in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of Formula I:



where:

A is $-CHR^{13}-$ or a bond;

R is hydrogen, halo, cyano, -C(O)NR^{6}R^7, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

R^1 is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or C_1-C_6 alkyl;

R^2 and R^3 are independently hydrogen, halo, amino, nitro, C_1-C_4 alkoxy, cyano, carboxamido, -C(O)NR^{8}R^9, -NR^{10}R^{11}, -NHC(O)NHR^{14}, C_1-C_4 alkoxycarbonyl, carboxyl, trifluoromethyl, or C_1-C_6 alkyl optionally substituted with a substituent selected from the group consisting of C_1-C_4 alkoxy, hydroxy, phenoxy, and phenyl;

R^4 and R$^{4'}$ are independently hydrogen, C_1-C_4 alkyl, or benzyl; or R^4 and R$^{4'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^5 is hydrogen, C_1-C_4 alkyl, or benzyl;

R$^{5'}$ is hydrogen, or R^5 and R$^{5'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^6 and R^7 are independently hydrogen or C_1-C_4 alkyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^9 is C_1-C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^{10} is hydrogen or C_1-C_4 alkyl;

R^{11} is C_1-C_4 alkyl or C_1-C_4 acyl;

R^{12} is hydrogen, halo, or C_1-C_4 alkyl;

R^{13} is hydrogen, C_1-C_4 alkyl, or benzyl;

R^{14} is hydrogen, C_1-C_4 alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

or pharmaceutically acceptable acid addition salts thereof.

3. A method for increasing activation of the 5-HT_{2C} receptor in mammals, comprising administering to a mammal in need of such activation a pharmaceutically effective amount of a compound of Formula I:



I

where:

A is -CHR^{13}- or a bond;

R is hydrogen, halo, cyano, -$C(O)NR^6R^7$, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

R^1 is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or C_1-C_6 alkyl;

R^2 and R^3 are independently hydrogen, halo, amino, nitro, C_1-C_4 alkoxy, cyano, carboxamido, -$C(O)NR^8R^9$, -$NR^{10}R^{11}$, -$NHC(O)NHR^{14}$, C_1-C_4 alkoxycarbonyl, carboxyl, trifluoromethyl, or C_1-C_6 alkyl optionally substituted with a substituent selected from the group consisting of C_1-C_4 alkoxy, hydroxy, phenoxy, and phenyl;

R^4 and $R^{4'}$ are independently hydrogen, C_1-C_4 alkyl, or benzyl; or R^4 and $R^{4'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^5 is hydrogen, C_1-C_4 alkyl, or benzyl;

$R^{5'}$ is hydrogen, or R^5 and $R^{5'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^6 and R^7 are independently hydrogen or C_1-C_4 alkyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^9 is C_1-C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^{10} is hydrogen or C_1-C_4 alkyl;

R^{11} is C_1-C_4 alkyl or C_1-C_4 acyl;

R^{12} is hydrogen, halo, or C_1-C_4 alkyl;

R^{13} is hydrogen, C_1-C_4 alkyl, or benzyl;

R^{14} is hydrogen, C_1-C_4 alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

or pharmaceutically acceptable acid addition salts thereof.

4. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



I

where:

A is $-CHR^{13}-$ or a bond;

R is hydrogen, halo, cyano, $-C(O)NR^6R^7$, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

R^1 is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or C_1-C_6 alkyl;

R^2 and R^3 are independently hydrogen, halo, amino, nitro, C_1-C_4 alkoxy, cyano, carboxamido, $-C(O)NR^8R^9$, $-NR^{10}R^{11}$, $-NHC(O)NHR^{14}$, C_1-C_4 alkoxycarbonyl, carboxyl, trifluoromethyl, or C_1-C_6 alkyl optionally substituted with a substituent selected from the group consisting of C_1-C_4 alkoxy, hydroxy, phenoxy, and phenyl;

R^4 and $R^{4'}$ are independently hydrogen, C_1-C_4 alkyl, or benzyl; or R^4 and $R^{4'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^5 is hydrogen, C_1-C_4 alkyl, or benzyl;

$R^{5'}$ is hydrogen, or R^5 and $R^{5'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^6 and R^7 are independently hydrogen or C_1-C_4 alkyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^9 is C_1-C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^{10} is hydrogen or C_1-C_4 alkyl;

R^{11} is C_1-C_4 alkyl or C_1-C_4 acyl;

R^{12} is hydrogen, halo, or C_1-C_4 alkyl;

R^{13} is hydrogen, C_1-C_4 alkyl, or benzyl;

R^{14} is hydrogen, C_1-C_4 alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

or pharmaceutically acceptable acid addition salts thereof.

5. A method for the treatment of depression in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



I

where:

A is $-CHR^{13}-$ or a bond;

R is hydrogen, halo, cyano, $-C(O)NR^6R^7$, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two

substituents selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;

R^1 is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or C_1-C_6 alkyl;

R^2 and R^3 are independently hydrogen, halo, amino, nitro, C_1-C_4 alkoxy, cyano, carboxamido, -C(O)NR^8R^9, -$NR^{10}R^{11}$, -NHC(O)NHR^{14}, C_1-C_4 alkoxycarbonyl, carboxyl, trifluoromethyl, or C_1-C_6 alkyl optionally substituted with a substituent selected from the group consisting of C_1-C_4 alkoxy, hydroxy, phenoxy, and phenyl;

R^4 and $R^{4'}$ are independently hydrogen, C_1-C_4 alkyl, or benzyl; or R^4 and $R^{4'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^5 is hydrogen, C_1-C_4 alkyl, or benzyl;

$R^{5'}$ is hydrogen, or R^5 and $R^{5'}$ together with the carbon atom to which they are attached form a cyclopropyl moiety;

R^6 and R^7 are independently hydrogen or C_1-C_4 alkyl;

R^8 is hydrogen or C_1-C_4 alkyl;

R^9 is C_1-C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^{10} is hydrogen or C_1-C_4 alkyl;

R^{11} is C_1-C_4 alkyl or C_1-C_4 acyl;

R^{12} is hydrogen, halo, or C_1-C_4 alkyl;

R^{13} is hydrogen, C_1-C_4 alkyl, or benzyl;

R^{14} is hydrogen, C_1-C_4 alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo, C_1-C_4 alkyl, and C_1-C_4 alkoxy;
or pharmaceutically acceptable acid addition salts thereof.

6. (once amended) A method of [any of] Claim[s] 3[, 4, or 5] where the mammal is human[;]
7. (new) A method of Claim 4 where the mammal is human;
8. (new) A method of Claim 5 where the mammal is human.

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/890,311	Karin Briner	X-11594

INTERNATIONAL APPLICATION NO.	
PCT/US00/01342	
I.A. FILING DATE	PRIORITY DATE
01/19/2000	

R Craig Tucker
Eli Lilly and company Patent Division
Lilly Corporate Center
Mc 416
Indianapolis, IN 46285-0002

CONFIRMATION NO. 8925

371
ABANDONMENT/TERMINATION LETTER

OC000000009112886

Date Mailed: 11/15/2002

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as an Elected Office (37 CFR 1.495), has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS, mailed 09/10/2001 within the time period set therein.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

SHELBY J VIGIL

Telephone: (703) 305-3653

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

US 0989031105P1

Creation date: 01-08-2004
Indexing Officer: NNGUYEN7 - NAM NGUYEN
Team: OIPEBackFileIndexing
Dossier: 09890311

Legal Date: 12-02-2002

No.	Doccode	Number of pages
1	BIB	1
2	OATH	5
3	PET.	3

Total number of pages: 9

Remarks:

Order of re-scan issued on .....